ALDH1A1 and carcinoma: The evaluation of cancer stem‐cell parameters demonstrated significant dose‐independent increase in the ALDH1A1 expression by 44.5% (P < 0.0001) in CLO 0.1 and 33% (P = 0.012) in CLO 1 and significant decreases in CD24 and CD44 expressions (however only in high‐dose CLO) by 57.5% (P = 0.0035) and 33% (P = 0.0063) in comparison with the control carcinomas (Fig. 3A).